Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM)

Next Previous
Trial Profile

A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM)

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SC 291 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Granulomatosis with polyangiitis; Lupus nephritis; Microscopic polyangiitis; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms GLEAM
  • Sponsors Sana Biotechnology

Most Recent Events

  • 25 Nov 2025 Planned number of patients changed from 36 to 7.
  • 25 Nov 2025 Status changed from recruiting to active, no longer recruiting.
  • 06 Nov 2025 According to Sana Biotechnology media release, status changed from active, no longer recruiting to suspended.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top